---

Highlights for September 2018

1. Aurobindo Pharma buys Sandoz's US business in US$900 Million deal.
2. Olon S.p.A., a world leading Active Pharmaceutical Ingredients (API) CDMO and generics supplier acquired an API manufacturing facility in Mahad, India.
3. Sun Pharma to acquire 18.75% stake in Israel's Tarsius Pharma Ltd for US$3 Million in cash.
4. Lupin partners with Eli Lilly to distribute and market Lilly's Aplevant (dulaglutide), a once-weekly injection for type-2 diabetes treatment in India.
5. UAE’s Neopharma buys US antibiotic manufacturing facility from Dr. Reddy’s.
6. Roche has paid US$81 Million upfront to buy Tusk Therapeutics.
7. Hologic adds Focal Therapeutics to its breast-conserving surgery portfolio for US$125 Million.
8. Allergan defuses Botox threat with US$195 Million Bonti buy.
9. Boehringer buys oncolytic virus startup ViraTherapeutics.
10. Supernus adds epilepsy candidate with US$185 Million Biscayne buy.
11. Mylan Buys Novartis’ Cystic Fibrosis Products for US$463 Million.
12. Boston Scientific acquires prostate spacer developer Augmenix in US$600 Million deal.
13. BTG snaps up Ireland’s Novate Medical in a deal worth up to US$150 Million.

Updates at Aagami: 

1. Aagami CEO completes fruitful two-week business trip to South Korea and Japan.
2. Aagami VP and CEO to participate in the upcoming BIO-Europe (Copenhagen, Denmark, November 5–7, 2018).